Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients

Detti, Beatrice; Scoccianti, Silvia; Di Cataldo, Vanessa; Monteleone, Eleonora; Cipressi, Samantha; Bordi, Lorenzo; Pellicanò, Gianni; Gadda, Davide; Saieva, Calogero; Greto, Daniela; Pecchioli, Guido; Buccoliero, Annamaria; Ceroti, Marco; Ammannati, Franco; Biti, Giampaolo
December 2013
Journal of Neuro-Oncology;Dec2013, Vol. 115 Issue 3, p421
Academic Journal
Meningiomas account for up to 20 % of all primary intracranial neoplasms; although the majority of these have a benign course, as many as 5–10 % can display more aggressive behavior and a higher incidence of disease progression. The benefit of immediate adjuvant radiotherapy is still being debated for atypical and malignant meningiomas. This study aimed to retrospectively assess prognostic factors and outcome in 68 patients with atypical and malignant meningiomas. Sixty-eight meningioma patients were treated with radiotherapy after initial resection or for recurrence, between January 1993 and December 2011. Surgery was macroscopically complete in 80 % of the patients; histology was atypical and malignant in 51 patients and 17 patients, respectively. Mean dose of radiotherapy was 54.6 Gy. Fifty-six percent of all patients received radiotherapy after surgical resection, 26 % at the first relapse, and 18 % at the second relapse. Median follow-up was 6.7 years, (range 1.5–19.9 years). The 5- and 10-year actuarial overall survival (OS) rates were 74.1 and 45.6 %, respectively. At univariate analysis age >60 years, radiotherapy dose >52 Gy showed statistical significance, ( p = 0.04 and p = 0.03, respectively). At the multivariate analysis radiotherapy dose >52 Gy maintained the statistical significance, ( p = 0.037). OS of patients treated with radiotherapy at diagnosis was longer than the survival of patients treated with salvage radiotherapy; however this difference did not reach statistical significance when tested for the entire series or for the subgroups of grade 2 and grade 3 patients. The 5- and 10-year disease-free survival (DFS) rates were 76.5 and 69.5 %, respectively, and were significantly influenced by size >5 cm ( p = 0.04) and grading ( p = 0.003) on univariate analysis. At multivariate analysis, size and grading both remained significant prognostic factors, p = 0.044 and p = 0.0006, respectively. Grade ≤ 2 acute side effects were seen during radiotherapy treatment in 16 % of the patients, with no ≥ grade 3 acute toxicity, based on the Common Terminology Criteria for Adverse Events. In this mono-institutional retrospective study, age and radiotherapy dose were associated with a longer OS, while preoperative size and grading of the tumor influenced DFS. Although there were some advantages in terms of OS for patients treated with postoperative radiotherapy, the benefit did not reach the significance. Multicenter prospective studies are necessary to clarify the management and the correct timing of radiotherapy in such a rare disease.


Related Articles

  • Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Imber, Brandon; Braunstein, Steve; Wu, Fred; Nabavizadeh, Nima; Boehling, Nicholas; Weinberg, Vivian; Tihan, Tarik; Barnes, Michael; Mueller, Sabine; Butowski, Nicholas; Clarke, Jennifer; Chang, Susan; McDermott, Michael; Prados, Michael; Berger, Mitchel; Haas-Kogan, Daphne // Journal of Neuro-Oncology;Jan2016, Vol. 126 Issue 1, p193 

    No abstract available.

  • Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor. Lester, Rachael; Brown, Lindsay; Eckel, Laurence; Foote, Robert; NageswaraRao, Amulya; Buckner, Jan; Parney, Ian; Wetjen, Nicholas; Laack, Nadia // Journal of Neuro-Oncology;Nov2014, Vol. 120 Issue 2, p371 

    Central nervous system primitive neuroectodermal tumors (CNS PNETs) predominantly occur in children and rarely in adults. Because of the rarity of this tumor, its outcomes and prognostic variables are not well characterized. The purpose of this study was to evaluate clinical outcomes and...

  • An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013. Pietschmann, Sophie; Bueren, André; Henke, Guido; Kerber, Michael; Kortmann, Rolf-Dieter; Müller, Klaus // Journal of Neuro-Oncology;Dec2014, Vol. 120 Issue 3, p451 

    Dissemination of high-grade gliomas (WHO IV) has been investigated poorly so far. We conducted an extensive analysis of the characteristics, treatments and outcomes of the glioblastoma multiforme (GBM)/gliosarcoma (GS) patients with central nervous system (CNS) metastases reported in literature...

  • The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. Yasui, Hironobu; Asanuma, Taketoshi; Kino, Junichi; Yamamori, Tohru; Meike, Shunsuke; Nagane, Masaki; Kubota, Nobuo; Kuwabara, Mikinori; Inanami, Osamu // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Glioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation. This radioresistance is partly due to the presence of a hypoxic region which is widely found in advanced malignant gliomas. In the present study, we evaluated the effectiveness of the...

  • Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Lim, Taekyu; Kim, Seok; Kim, Kihyun; Lee, Jung-Il; Lim, Do; Lee, Duk; Baek, Kyung; Lee, Ha; Han, Boram; Uhm, Ji; Ko, Young; Kim, Won; Kim, Seok Jin; Lim, Do Hoon; Lee, Duk Joo; Baek, Kyung Kee; Lee, Ha Yeon; Uhm, Ji Eun; Ko, Young Hyeh; Kim, Won Seog // Annals of Hematology;Dec2011, Vol. 90 Issue 12, p1391 

    Diffuse large B-cell lymphoma (DLBCL) constitutes most primary central nervous system (CNS) lymphoma (PCNSL), whereas T-cell, low-grade and Burkitt's lymphomas (BL) are rarely encountered. Due to the paucity of cases, little is known about the clinical features and treatment outcomes of PCNSL...

  • Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy. Ding, Dale; Yen, Chun-Po; Starke, Robert; Lee, Cheng-Chia; Sheehan, Jason // Journal of Neuro-Oncology;Sep2014, Vol. 119 Issue 3, p513 

    In the past decade, our understanding of the roles of external beam radiotherapy (EBRT) and stereotactic radiosurgery (SRS) in the management of brain tumors has dramatically improved. To highlight the changes and contemporary treatment approaches, we review the indications and outcomes of...

  • The development of a clinical registry for gamma knife radiosurgery in pittsburgh. Berkowitz, O.; Kondziolka, D.; Bissonette, D.; Niranjan, A.; Kano, H.; Lunsford, L. D. // Journal of Radiosurgery & SBRT;2013 Supplement 2.1, Vol. 2, p61 

    Objectives: The introduction of the first North American 201 Cobalt 60 Gamma Knife Radiosurgery® (GKR) device to the University of Pittsburgh Medical Center in 1987 prompted the desire to study the effectiveness of this technique and evaluate patient outcomes. This surgical procedure was...

  • High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. John Watkins; David Marshall; Sunil Patel; Pierre Giglio; Amy Herrin; Elizabeth Garrett-Mayer; Joseph Jenrette // Journal of Neuro-Oncology;Jul2009, Vol. 93 Issue 3, p343 

    Abstract   Objectives To describe outcomes associated with high-dose radiotherapy with and without temozolomide for high grade central nervous system (CNS) neoplasms. Methods Retrospective chart review of 60 patients diagnosed with malignant glioma treated with ≥70 Gy...

  • Radiotherapy Dose Fractionation under Parameter Uncertainty. Davison, Matt; Kim, Daero; Keller, Harald // AIP Conference Proceedings;11/27/2011, Vol. 1368 Issue 1, p179 

    In radiotherapy, radiation is directed to damage a tumor while avoiding surrounding healthy tissue. Tradeoffs ensue because dose cannot be exactly shaped to the tumor. It is particularly important to ensure that sensitive biological structures near the tumor are not damaged more than a certain...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics